Colorectal cancer metastatic

36 trials 16 recruiting MedDRA PT
36 Registered trials
16 Recruiting
29 Unique sponsors
50 Unique IMPs
16 Commercial trials
Drug classes (ATC)
— ATC code not specified 16
L Oncology (ATC L) 19
N Neurology/Psychiatry (ATC N) 3
V Various (ATC V) 2
B Haematology (ATC B) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 19 substances
Antimetabolite 4 substances
Kinase inhibitor 4 substances
Monoclonal antibody (tumor, humanized) 3 substances
Monoclonal antibody 2 substances
CDK inhibitor 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Antibody-drug conjugate (ADC) 1 substance
RAF/BRAF inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Supportive / rescue 1 substance
Topoisomerase I inhibitor 1 substance
Monoclonal antibody (human) 1 substance
Receptor fusion protein 1 substance
mTOR inhibitor 1 substance
HDAC inhibitor 1 substance
PARP inhibitor 1 substance
BCL-2 inhibitor 1 substance
Heparin / LMWH 1 substance
Phase III: 8 Phase II/III: 1 Phase II: 15 Phase I/II: 5 Phase I: 3 Phase I (Other): 3 Phase I (First in Human): 2

Filter these 36 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 36 trials

Phase III

8 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB, RELATLIMAB; REGORAFENIB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
    2023-503797-21-00 10 countries 2022 n=233
    Ended
  • Incyte Corp. Commercial
    INCA33890
    2025-523735-19-00 10 countries n=292
    Pending
  • Institut De Recherches Internationales Servier IRIS Commercial
    BEVACIZUMAB; CAPECITABINE; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
    2024-516180-85-00 4 countries 2019 n=84
    Recruiting
  • Mirati Therapeutics Inc. Commercial
    ADAGRASIB; CETUXIMAB
    2023-506241-30-00 15 countries 2021 n=199
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2023-504831-42-00 1 country 2025 n=254
    Recruiting
  • Centre Hospitalier Universitaire Rouen Academic
    ANHYDROUS CYCLOPHOSPHAMIDE; CAPECITABINE; D,L-LYSINE ACETYLSALICYLATE; REGORAFENIB
    2023-509761-21-00 1 country 2024 n=174
    Recruiting
  • Grupo Gallego De Investigacion En Tumores Digestivos Academic
    TINZAPARIN SODIUM
    2023-508860-31-00 2 countries 2023 n=631
    Ended
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    PANITUMUMAB
    2023-509551-14-00 1 country 2024 n=500
    Recruiting

Phase II/III

1 trial
  • Universitaetsklinikum Heidelberg AöR Academic
    IMP not specified
    2023-509771-17-00 1 country 2024 n=80
    Ended

Phase II

15 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    TELISOTUZUMAB ADIZUTECAN
    2023-505110-14-00 3 countries 2024 n=61
    Ended
  • Leap Therapeutics Inc. Commercial
    BEVACIZUMAB; FLUOROURACIL; OXALIPLATIN; SIREXATAMAB
    2022-501465-40-00 1 country 2023 n=25
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2024-512119-34-00 12 countries 2022 n=75
    Recruiting
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    REGORAFENIB
    2024-517241-13-00 1 country 2021 n=110
    Ended
  • Grupo Espanol Multidisciplinar En Cancer Digestivo Academic
    BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; PANITUMUMAB
    2024-517782-16-00 1 country 2024 n=45
    Ended
  • Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets Academic
    PEMBROLIZUMAB
    2024-518526-33-01 1 country 2025 n=822
    Ended
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PANITUMUMAB
    2024-514420-16-00 1 country 2024 n=130
    Recruiting
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    IMP not specified
    2024-518987-11-00 1 country 2019 n=34
    Recruiting
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    AFLIBERCEPT; CALCIUM LEVOFOLINATE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; OXALIPLATIN; REGORAFENIB
    2024-519669-23-00 1 country 2025 n=60
    Recruiting
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic
    AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS; BEVACIZUMAB; PEMBROLIZUMAB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
    2024-514053-30-00 1 country 2025 n=36
    Recruiting
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic
    ALDESLEUKIN; AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELLS
    2024-516221-31-00 1 country 2016 n=19
    Recruiting
  • Oslo University Hospital HF Academic
    ALECTINIB; BINIMETINIB; CRIZOTINIB; DASATINIB; EVEROLIMUS; GEMCITABINE; IDELALISIB; METHOTREXATE; PALBOCICLIB; PANOBINOSTAT; PEMBROLIZUMAB; PERTUZUMAB; TALAZOPARIB; TRASTUZUMAB; VENETOCLAX
    2023-510092-62-00 1 country 2022 n=45
    Recruiting
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2023-509619-10-00 1 country 2024 n=60
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    REGORAFENIB
    2024-517241-13-00 1 country 2021 n=110
    Ended

Phase I/II

5 trials
  • BioNTech SE Commercial
    BNT314; BNT327; PUMITAMIG
    2025-521768-36-00 2 countries 2026 n=168
    Recruiting
  • Cyclacel Limited Commercial
    FADRACICLIB
    2024-516289-12-00 1 country 2022 n=30
    Ended
  • Oncolytics Biotech Inc. Commercial
    ATEZOLIZUMAB; PELAREOREP
    2024-515936-62-00 1 country 2024 n=102
    Ended
  • AIO-Studien gGmbH Academic
    METHADONE HYDROCHLORIDE
    2024-519509-37-00 1 country 2025 n=84
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    CAPECITABINE; GALUNISERTIB
    2024-518980-37-00 1 country 2023 n=31
    Recruiting

Phase I

3 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2022-501570-18-00 3 countries 2023 n=145
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2024-514704-13-00 1 country n=30
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2023-503409-12-00 1 country 2020 n=24
    Ended

Phase I (Other)

3 trials
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID; AZENOSERTIB
    2024-511227-33-00 1 country n=43
    Suspended
  • Universitair Medisch Centrum Utrecht Academic
    IMP not specified
    2023-509183-17-00 1 country 2024 n=45
    Recruiting
  • Universitair Medisch Centrum Utrecht Academic
    IMP not specified
    2024-512301-16-01 1 country 2024 n=25
    Recruiting

Phase I (First in Human)

2 trials
  • Merus B.V. Commercial
    PEMBROLIZUMAB; PETOSEMTAMAB
    2024-513627-16-01 5 countries 2018 n=395
    Recruiting
  • Pfizer Inc. Commercial
    PF-07220060 MONOHYDRATE
    2024-512120-11-00 2 countries 2022 n=62
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic 4 Phase II, Phase III 4
Pfizer Inc. Commercial 2 Phase II, Phase I (First in Human) 1
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic 2 Phase I (Other), Phase I/II 1
Universitair Medisch Centrum Utrecht Academic 2 Phase I (Other) 2
Centre Hospitalier Universitaire De Nantes Academic 2 Phase II 0
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. Academic 2 Phase II 2
AstraZeneca AB Commercial 1 Phase I 0
BeOne Medicines AG Commercial 1 Phase I 0
Genentech Inc. Commercial 1 Phase I 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase II 0
Leap Therapeutics Inc. Commercial 1 Phase II 0
Seagen Inc. Commercial 1 Phase II 0
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Incyte Corp. Commercial 1 Phase III 0
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase III 1
Mirati Therapeutics Inc. Commercial 1 Phase III 0
Merus B.V. Commercial 1 Phase I (First in Human) 1
BioNTech SE Commercial 1 Phase I/II 1
Cyclacel Limited Commercial 1 Phase I/II 0
Oncolytics Biotech Inc. Commercial 1 Phase I/II 0
New trials by year
2019
3
2020
1
2021
3
2022
5
2023
4
2024
10
2025
5
2026
1
← All indication landscapes